Analytical Data
-
Gene name
Elastase IIIB/CELA3B
- Application
-
Alternative Names
CELA3B; Chymotrypsin Like Elastase Family Member 3B; Protease E; Fecal Elastase; Elastase 1; Cholesterol-Binding Pancreatic Protease; Pancreatic Endopeptidase E
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P08861
-
Expression Region
Val29~His270
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Elastase IIIB, also known as CELA3B, is a member of the serine protease family and is primarily involved in the degradation of extracellular matrix components, particularly elastin. This enzyme is produced predominantly in the pancreas and is associated with various physiological and pathological processes, including tissue remodeling, inflammation, and immune responses. Studies have indicated that CELA3B plays a role in chronic diseases such as emphysema and acute pancreatitis, where its activity can influence the extent of tissue damage and inflammatory responses. The recombinant production of Elastase IIIB/CELA3B has become an area of interest, enabling researchers to investigate its structural properties and functional mechanisms in detail. By expressing this enzyme in suitable host systems, scientists can produce sufficient quantities for biochemical assays and structural studies, facilitating a better understanding of its substrate specificity and potential therapeutic roles. Furthermore, the development of CELA3B as a research tool may pave the way for novel therapeutic strategies targeting diseases linked to aberrant elastolytic activity. Overall, the study of recombinant elastase IIIB/CELA3B holds promise for advancing our knowledge of both fundamental enzymatic processes and their implications in disease pathology.
